Table 1.
Baseline characteristics of participants
| Characteristics | Participant number (%) |
|---|---|
| Participants enrolled | N = 110 |
| Planned trips | N = 99 |
| Participants who returned swabs | N = 64 |
| Trips with returned swabs | N = 72 |
| Gender, Male | 81 (74%) |
| Median age (years) | 38 (IQR 31,47.25) |
| Median duration of travel (days) | 21 (IQR 12.75, 79.5) |
| Region of travel | N = 72 |
| Mexico, Caribbean and Central America | 12 (17%) |
| Asia | 11 (15%) |
| Africa | 41 (57%) |
| South America | 7 (10%) |
| Living conditions | |
| Hotel with air conditioning | 32 (56%) |
| Hotel without air conditioning | 8 (11%) |
| Military accommodations | 4 (6%) |
| Dormitories/Barracks | 36 (50%) |
| Field water exposure* | 5 (7%) |
| Local water ingestion | |
| Untreated water | 1 (1%) |
| Ice in beverage | 31 (43%) |
| Antimicrobial exposure since enrollment | 58 (81%) |
| Malaria prophylaxis | 57 (79%) |
| Chloroquine | 2 (3%) |
| Mefloquine | 0 (0%) |
| Atovaquone–proguanil | 45 (63%) |
| Doxycycline | 11 (15%) |
| Primaquine | 9 (13%) |
| Antibiotics for TD | 8 (11%) |
| Ciprofloxacin | 4 (6%) |
| Azithromycin | 3 (4%) |
| Levofloxacin | 1 (1%) |
| Systemic antibiotics for other reasons | 3 (4%) |
| Amoxicillin/clavulanate | 1 (1%) |
| Levofloxacin | 1 (1%) |
| Trimethoprim/sulfamethoxazole | 1 (1%) |
| Illness since enrollment | 19 (27%) |
| Fever | 0 (0%) |
| Influenza like illness | 9 (13%) |
| TD | 10 (14%) |
*Defined as contact with fresh water from lakes, streams or rivers (wading/bathing/swimming/etc.).